Vangelis Manolopoulos is a distinguished member of the faculty at Democritus University of Thrace Medical School in Alexandroupolis, where he has been shaping the future of pharmacology since 1998. Holding the prestigious titles of full professor of Pharmacology, Pharmacogenomics & Precision Medicine, he leads both the department of Pharmacology at DUTH and the Clinical Pharmacology Unit at the Academic Hospital of Evros with notable expertise. His role extends to directing the Masters’ Course on Clinical Pharmacology and Therapeutics at DUTH, further showcasing his commitment to advancing medical education and research.
Manolopoulos embarked on his academic journey with a Ph.D. in pharmacology from the Medical School of Patras University in 1991, with part of his doctoral research conducted at the University of Groningen, Netherlands. His postdoctoral pursuits took him to the Milwaukee Clinical Campus of the University of Wisconsin, USA, and later to the Katholic University’s Medical School in Leuven, Belgium, enriching his expertise in physiology.
Since 1999, Manolopoulos has been imparting knowledge on basic and clinical pharmacology to medical students, and in 2001, he pioneered a course in Pharmacogenetics, marking one of the first such courses to be integrated into an undergraduate medical curriculum globally. His scholarly contributions exceed 150 research publications, with his research primarily focusing on the pharmacogenomics and epigenomics of drugs for treating cardiovascular diseases, diabetes, and psychiatric conditions. Additionally, he has a profound interest in cardiovascular disease pathophysiology and endothelial cell biology.
Manolopoulos’ leadership extends beyond academia; he currently chairs the Greek National Organization for Medicines (EOF) and has held significant positions such as the Principal Investigator for Greece in the EU-PACT and Chair of the European Society for Pharmacogenomics and Personalized Therapy (ESPT). His influence also reached the Greek Society for Pharmacology and Clinical Pharmacology and the European Association for Clinical Pharmacology (EACPT). As an associate editor and member of executive editorial boards for several prestigious journals, he contributes to the broader scientific dialogue. His expertise is frequently sought in national and international grant proposal evaluations, particularly within EU funding programs, highlighting his role in shaping the future of pharmacology and personalized medicine